Browse the evidence

n-6 fatty acids, specifically arachidonic acid (AA), increase the susceptibility of cardiomyocytes to apoptosis and arrhythmias during ischemia/reperfusion injury through Ca2+/Na+ mediated actions and increased inflammatory biomarkers.

Maintain a healthy balance between n-6 and n-3 fatty acids. While n-6 fats are essential, excessive intake relative to n-3 fats may increase inflammation and heart cell damage during stress. Focus on reducing processed foods high in n-6 oils and increasing n-3 sources.

Combined GIPR/GLP1R agonism significantly attenuates atherosclerosis severity (shifting lesions from severe to mild) in APOE*3-Leiden.CETP mice, an effect not achieved by single GIPR or GLP1R agonism.

This pre-clinical study suggests that combining GIP and GLP-1 receptor agonism may offer superior protection against atherosclerosis severity compared to using either hormone alone. For humans, this supports the development and use of dual-agonist therapies (like tirzepatide) for cardiovascular risk reduction, particularly in those with obesity and dyslipidemia, though clinical confirmation is required.

In obese patients without preexisting osteoarthritis, GLP-1 receptor agonist use is associated with an increased incidence of new hip and knee OA diagnoses and conversion to total knee arthroplasty within one year.

If you are obese but do not have existing hip or knee osteoarthritis, using a GLP-1 receptor agonist is associated with a higher risk of being diagnosed with new OA or needing knee replacement surgery within a year. This is unexpected given the weight loss benefits, and researchers suggest it might be due to increased physical activity stressing the joints. If you are considering these medications, discuss your joint health history with your doctor, and be aware that the benefits for joint health may primarily apply to those who already have OA.

Long-term administration of the dual GLP-1/GIP receptor agonist tirzepatide suppresses mammary tumor growth in diet-induced obese mice by reversing metabolic dysregulation and restoring CD8+ T cell function.

For individuals with obesity and hormone-sensitive or obesity-linked cancers, GLP-1/GIP agonists like tirzepatide may offer a dual benefit of weight loss and tumor suppression by correcting metabolic dysregulation. This suggests that treating obesity pharmacologically could be a viable adjunct strategy in oncology, provided lean mass is monitored.

The proposed mechanism for this hearing loss is the suppression of matrix metalloproteinase-9 (MMP-9) by exendin-4 derivatives, leading to micro-platelet-erythrocyte clot formation and occlusion of cochlear micro-circulation.

This mechanism is currently theoretical. While it provides a plausible biological explanation for why Lixisenatide might affect hearing, it has not been directly proven in human trials yet.

Intestinal GLP-1 from colonic L-cells is likely not involved in the acute control of meal size or thirst, but may play a role in long-term fluid balance and cardiovascular function.

The GLP-1 produced in your large intestine (colon) likely doesn't help you feel full or stop drinking during a meal. Its role is more about long-term fluid and heart health regulation, distinct from the GLP-1 produced in the small intestine which helps control appetite.

Tirzepatide (TZP) administration causes bone loss in obese diabetic mice by reducing gut microbiota biodiversity, specifically depleting Lachnospiraceae, which leads to lower levels of the metabolite evodiamine and subsequent increased osteoclastogenesis.

If you are taking Tirzepatide for diabetes or obesity, be aware that it may reduce bone density in your hips/femurs by altering gut bacteria. Discuss bone health monitoring with your doctor. The study suggests that maintaining gut health (specifically Lachnospiraceae bacteria) might protect bone, though probiotic supplementation is not yet a standard prescription.

Monogenic diabetes, representing 1-4% of diabetes cases in infants and young adults, is frequently misdiagnosed as Type 1 or Type 2 diabetes, leading to inappropriate therapeutic management and worsened prognosis.

If a child or young adult is diagnosed with diabetes, ask if genetic testing for monogenic forms has been considered. Misdiagnosis as T1 or T2 can lead to incorrect treatment and worse outcomes, as monogenic diabetes often requires specific therapies different from standard insulin or oral agents.

Machine learning-guided optimization of triple agonist peptides (GCGR, GLP1R, GIPR) using Graph Attention Networks and genetic algorithms generates peptide sequences with high predicted binding affinity across all three targets, demonstrating superior computational performance over traditional Convolutional Neural Networks for GCGR prediction.

This research does not yet offer a direct treatment for patients. It describes a computational method to design better diabetes and obesity drugs. The key takeaway is that using advanced AI (Graph Attention Networks) to design peptides that target three metabolic receptors (GCGR, GLP1R, GIPR) simultaneously is more effective than older methods. This could lead to more potent drugs in the future, but no such drug is currently available for clinical use based on this paper alone.

Knockout of the lineage-specific microprotein Adipocyte-smORF-1183 significantly impairs adipocyte differentiation and reduces lipid droplet formation by approximately 50% in 3T3-L1 cells.

This research identifies a specific microprotein (Adipocyte-smORF-1183) in mouse fat cells that helps store fat. Knocking it out reduces fat storage by half in these cells. This is a basic science discovery about how fat cells work and does not currently translate to a human treatment or supplement.

Perioperative GLP-1 receptor agonist therapy does not significantly reduce periprosthetic joint infection or revision rates in patients undergoing total knee arthroplasty.

If you are having knee replacement, current evidence does not show that GLP-1 agonists reduce infection or revision risk. Discuss with your surgeon, but do not expect the same benefits seen in hip surgery.

Perioperative use of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) may increase the risk of bronchoaspiration.

Clinicians should be cautious about the use of GLP-1-RAs in the perioperative setting due to the risk of bronchoaspiration.

Inhibiting miR-30e-5p using antagomirs reduces atherosclerosis in obese mouse models by restoring SLC7A11 expression and improving endothelial mitochondrial function.

While not yet a human treatment, this finding suggests that future therapies could target the specific signals fat cells send to blood vessels. For now, maintaining a healthy weight remains the most effective way to prevent these damaging signals from accumulating.

Sustained activation of pancreatic Y1 receptors improves beta-cell turnover, preserves beta-cell identity, and enhances insulin secretory responsiveness in rodent models of diabetes.

Sustained Y1 receptor activation improves beta-cell function in rodents, suggesting potential anti-diabetic benefits.

Jatobá-do-cerrado polyphenol extracts reduce glucose uptake and downregulate the gene expression of glucose transporters SGLT1 and GLUT2 in Caco-2 cells in a dose-dependent manner.

Lab studies show that jatobá polyphenols can reduce how intestinal cells absorb glucose and lower the expression of key glucose transporters. This suggests a potential mechanism for blood sugar control, but human studies are needed to confirm this effect.

Intergenerational transmission of risk via microbiome, epigenetics, and noncoding RNAs (ncRNAs) contributes to the obesity epidemic by increasing susceptibility to weight gain in offspring of obese parents, independent of current energy intake.

If you have a family history of obesity, focus on a healthy diet and lifestyle for yourself and your children. This can help mitigate the biological risks transmitted through the microbiome and epigenetics.

Inadvertent exposure to GLP-1 receptor agonists during pregnancy does not appear to pose a significant teratogenic risk, with congenital abnormality rates in exposed pregnancies being lower than or comparable to placebo groups.

If you took a GLP-1 medication (like Ozempic or Wegovy) before knowing you were pregnant, current data from clinical trials does not show an increased risk of birth defects compared to women who did not take these medications. You should stop the medication as soon as you know you are pregnant and consult your doctor for standard prenatal care.

Bariatric surgery, specifically Roux-en-Y gastric bypass (RYGB), improves metabolic health partly by activating the endocannabinoid system (CB-1) to increase sympathetic nerve activity and promote white adipose tissue browning.

If you are considering bariatric surgery, understand that it works by changing how your body signals hunger and burns energy, not just by restricting food intake. Discuss all options with your healthcare provider.

In vitro treatment with eicosapentaenoic acid (EPA) inhibits myotube formation and overrides the stimulatory effects of 17β-estradiol (E2) on myoblast differentiation.

If you are taking hormone replacement therapy (HRT) and considering high-dose fish oil supplements, be aware that they might not work together to build muscle as expected. This lab study suggests that high levels of EPA can actually block the muscle-building benefits of estrogen. Consult your doctor before combining these, especially if muscle maintenance is a primary goal.

There is insufficient evidence to support a causal relationship between GLP-1 receptor agonists and the risk of other common mental illnesses, including ADHD, Anorexia Nervosa, Autism Spectrum Disorder, and PTSD.

Based on this genetic study, GLP-1 drugs do not appear to reduce the risk of ADHD, Anorexia, Autism, or PTSD. Patients with these conditions should not rely on GLP-1 medications as a treatment for their mental health symptoms. Further research is needed to confirm these negative findings.

Current clinical practice for prescribing semaglutide for weight loss lacks comprehensive pretreatment screening for thyroid, pancreatic, and retinal risks, exposing patients to severe adverse outcomes.

If you are starting semaglutide for weight loss, ensure your doctor checks your calcitonin, pancreatic enzymes (lipase/amylase), and family history of thyroid cancer before starting. Standard blood tests are not enough to rule out serious risks associated with this medication.

High coffee consumption during pregnancy is associated with increased risks of low birth weight, preterm birth, and pregnancy loss.

If you are pregnant, high coffee consumption is linked to risks like low birth weight and preterm birth. It is advisable to limit intake or avoid high levels of consumption during pregnancy.

Insulin and corticosteroids (dexamethasone) act synergistically to induce PPAR-gamma1 and PPAR-gamma2 mRNA expression in isolated human adipocytes.

In fat cells, high levels of insulin and stress hormones (like cortisol/dexamethasone) work together to increase the expression of PPAR-gamma, a key driver of fat cell formation. This suggests that conditions involving both high insulin and high stress/cortisol may promote adipogenesis through this synergistic molecular pathway.

Pioglitazone (30 mg daily) improves biochemical and histological features of nonalcoholic steatohepatitis (NASH) in nondiabetic patients by redistributing lipid from the liver to peripheral adipose tissue, thereby reducing hepatic steatosis and inflammation.

For individuals with biopsy-proven NASH who are not diabetic, pioglitazone (30mg/day) can significantly improve liver inflammation and fat content over 48 weeks. However, this benefit comes with an average 4% weight gain due to increased body fat. This treatment requires strict medical supervision and monitoring, as it is not a routine therapy and long-term safety is still under study.